CRDF Cardiff Oncology, Inc. Common Stock

XNAS 0.80 Delayed
Find condors

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

CRDF $0.80 —
Key stats
$0.80
Pre-market $0.81 +0.30%
52-Week Range
$0.76 – $3.31
YTD
-69.95%
Straddle Price
$0.75
P/C Vol Ratio
0.11
Market Cap
$0.1B
Open
$0.89
Day Range
$0.79 – $0.95
Volume
868,019
Prev Close
$0.91
Fair Value
MODEL: LONG

A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.

  • DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
  • Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
  • DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
  • P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
  • Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
  • Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
  • Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
  • Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
10-yr Treasury (rf)4.96%
Beta vs SPY1.43
Cost of Equity (CAPM)12.85% (VRP-adj)
WACC12.99%
Volatility Risk Premium+388.9pp (IV − HV30), ERP adj +50bps
Effective Tax Rate21.0%
Rev. Growth (YoY, DCF input)-10.0%
DCF Horizon10 years explicit + fade
Free Cash Flow (TTM)$-0.0B
Return on Equity (TTM)-151.0%
Book / Price48.7% — banking bias active (P/B is primary)
Gross Margin (TTM)100.0%
FCF Margin (TTM)-8054.3%
Debt / Equity0.00
Quality Score2/6 — normal (10y DCF)
SMA 50$1.08 (Market Anchor value)
SMA 20 / Bollinger Mid$1.02
Bollinger Width / SMA204211.6% (drives anchor stability)
Net Debt$-0.0B
Market Cap$0B
Peers used for multiples: AMGN, BIIB, EXEL, GILD, HALO, MRNA, NBIX, RGEN, RVMD, TECH (SIC-code peers; ETF co-membership was sector-incoherent)
60-Day Conviction
94%
20-Day Fair Value
≈ by Nov 25, 2026
ACTIVE
$0.81
α +0.8% rank 96%
conviction
48%
40-Day Fair Value
≈ by Dec 24, 2026
ACTIVE
$0.82
α +2.5% rank 97%
conviction
76%
60-Day Fair Value
≈ by Jan 22, 2027
ACTIVE
$0.84
α +4.9% rank 96%
conviction
94%
MethodImplied PriceWeightDetail
DCF n/a 0%
DDM (Gordon) n/a 0%
Peer P/E n/a 0% median 34.5× · 7 peers
Peer EV/EBITDA n/a 0% median 18.3× · 8 peers
Peer P/B $4.01 18% median 10.2× · 10 peers
Peer P/S $0.05 18% median 6.6× · 9 peers
Market Anchor (SMA50) $1.08 64% stability 69% (BB-width)
Options Expected (B-L 30d) $0.92 0% 5 strikes · skew +0.05
As of 2026-10-27 · updated
About
Industry (SIC)
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) (2836) · industry map
Exchange
XNAS
Market Cap
$0.1B
Employees
31
List Date
1997-05-22
CIK
0001213037
Next Earnings
2026-11-05 (Pre-Market)
EPS Forecast
($0.14) (4 est.)
Headquarters
San Diego, CA
Homepage
https://www.cardiffoncology.com

Cardiff Oncology Inc is a clinical-stage biotechnology company advancing cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Its main asset, onvansertib, is a specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single agent clinical ac…

Summary
—
composite
—
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart
Seasonality
'21'22'23'24'25'26Avg
Jan-33.07%-47.43%20.95%1.96%-5.40%-34.21%-16.20%
Feb-12.37%-24.01%1.17%8.95%5.74%13.45%-1.18%
Mar-13.78%-7.81%-4.07%83.51%-17.69%-16.49%3.95%
Apr3.01%-46.18%8.07%-23.91%-10.46%7.45%-10.34%
May-12.32%-6.25%-13.44%-24.82%25.83%11.11%-3.31%
Jun-17.49%78.86%-6.96%-29.97%-5.97%-12.16%1.05%
Jul-20.00%-5.15%28.26%14.15%-32.48%-33.95%-8.20%
Aug34.74%38.66%-0.54%0.00%-20.45%6.38%9.80%
Sep-9.02%-45.77%-24.86%21.92%5.64%17.48%-5.77%
Oct-18.92%4.49%-17.69%26.32%12.98%-31.84%*-4.11%
Nov-10.37%-0.63%17.14%-18.56%-1.30%---2.74%
Dec16.02%-5.41%17.46%63.16%29.49%--24.14%
Total-68.84%-76.72%10.91%90.77%-28.53%-63.22%-22.61%
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $1.02
SMA 50: $1.08
SMA 200: $1.48
Current: $0.80
EMA 12: $0.95
EMA 26: $1.02
MACD: -0.0747 | Signal: -0.0197
BEARISH
ADX (14): 27.42
TREND
+DI: 11.55
−DI: 31.44

Momentum Oscillators

RSI (14): 26.71
OVERSOLD
Stoch %K: 10.39
Stoch %D: 14.02
Williams %R: -95.79

Volume & Volatility

BB Upper: $1.24
BB Lower: $0.80
NEUTRAL
OBV: -15,415,294
Vol SMA 20: 448,613
Vol ROC: 128.71%
ATR: $0.08
True Range: $0.16
HV 20: 63.3%
HV 30: 58.0%
HV 60: 72.1%

Data Summary

Data Points: 500
Last Updated:
Date Range: 2024-10-28T00:00:00 – 2026-10-26T00:00:00
AI Analysis

LLM Stock Analysis Report

Executive Summary

Overall Assessment: NEUTRAL (Confidence Level: 6/10)

Key Drivers:

  • Recent positive news headlines on CRDF's Phase 2 trial results for Onvansertib
  • High volatility, indicating market uncertainty and potential for significant price movements

Primary Risks:

  • Bearish MACD signal with a histogram reading -0.11
  • Low RSI level at 51.02, indicating a potentially overbought market

Investment Thesis: CRDF's recent positive news headlines on Phase 2 trial results may continue to drive short-term momentum, but the bearish MACD signal and low RSI level suggest potential for pullbacks or consolidation. As such, it is essential to monitor the stock's technical indicators and adjust positioning accordingly.

Recent News Sentiment Impact: The positive news headlines have contributed to a neutral overall sentiment assessment, as they are balanced by the bearish MACD signal.

Technical Analysis

Trend Direction:

  • Short-term (1-4 weeks): NEUTRAL
  • Medium-term (1-3 months): BEARISH
  • Long-term (3-12 months): BULLISH

Support/Resistance Levels:

  • Upper Bollinger Band: $1.22
  • Middle Bollinger Band: $0.92
  • Lower Bollinger Band: $0.63
  • SMA 20: $0.92
  • EMA 12: $0.94

Momentum Signals:

  • RSI interpretation: Neutral (51.02)
  • MACD signal: Bearish (-0.08 / Signal: 0.04 / Histogram: -0.11)
  • Bollinger Bands position: Squeeze

Volume Analysis:

  • Volume SMA 20: 1699105.45
  • On-Balance Volume (OBV): -13373304.11
  • Volume Rate of Change: -13.78%

News & Sentiment Analysis

Recent Headlines Summary: The recent news headlines have been predominantly positive, highlighting CRDF's Phase 2 trial results and upcoming presentations.

Sentiment Assessment: POSITIVE (70%)

Catalyst Identification: Upcoming ASCO presentation and potential regulatory approvals.

Market Narrative: The market narrative suggests that the recent positive news headlines are driving short-term momentum, but the bearish MACD signal and low RSI level indicate potential for pullbacks or consolidation.

Risk & Volatility Assessment

Beta Interpretation: High risk (beta >1.5)

Volatility Regime: High volatility (current vs historical)

Options Market Signals: IV rank: 37.9% (Medium), put/call ratios: 0.12 (Bullish sentiment)

Downside Protection: Support levels and risk management considerations are essential, given the high beta and volatility.

Market Context & Positioning

Sector Performance: Cancer sector performing well, with CRDF's Phase 2 trial results driving momentum.

Institutional Activity: Institutional interest is evident, as demonstrated by volume patterns suggesting significant buying pressure.

Correlation Analysis: CRDF has a relatively high correlation coefficient (0.34) with the broader market, indicating that it tends to move in tandem with the overall market.

Relative Valuation: CRDF's valuation relative to its peers and industry is neutral.

Key Levels & Action Items

Critical Price Levels:

  • Upper Bollinger Band: $1.22
  • Middle Bollinger Band: $0.92
  • Lower Bollinger Band: $0.63
  • SMA 20: $0.92
  • EMA 12: $0.94

Breakout/Breakdown Levels:

  • Potential resistance at the upper Bollinger Band: $1.22
  • Potential support at the lower Bollinger Band: $0.63

Time-Sensitive Catalysts: ASCO presentation and potential regulatory approvals.

Risk Management: Stop-loss levels should be set to minimize potential losses, considering the high beta and volatility.

Generated
Earnings History
19 of 19 under expected move
Avg Expected Move
39.29%
Avg Actual Move
5.83%
Each row pairs the pre-earnings straddle-implied expected move with the realized close-to-close move. Sorted oldest first.
Earnings Date Timing Expected Move Actual Move Ratio Outcome
2021-02-25 Pre-Market 25.58% 5.16% 0.20x Within
2021-05-06 Pre-Market 19.22% 10.26% 0.53x Within
2021-08-05 Pre-Market 18.16% 2.79% 0.15x Within
2021-11-04 Pre-Market 27.05% 0.16% 0.01x Within
2022-02-24 Pre-Market 24.25% 0.37% 0.02x Within
2022-08-04 Pre-Market 25.00% 10.00% 0.40x Within
2022-11-03 Pre-Market 71.14% 4.70% 0.07x Within
2023-05-04 Pre-Market 37.63% 4.84% 0.13x Within
2023-08-09 Pre-Market 41.28% 12.39% 0.30x Within
2024-02-29 Pre-Market 44.51% 3.02% 0.07x Within
2024-05-02 Pre-Market 34.52% 5.91% 0.17x Within
2024-08-08 Pre-Market 44.39% 0.47% 0.01x Within
2024-11-07 Pre-Market 45.28% 7.35% 0.16x Within
2025-02-27 After-Close 26.48% 4.43% 0.17x Within
2025-05-08 Pre-Market 32.13% 5.62% 0.17x Within
2025-07-29 After-Close 64.20% 24.77% 0.39x Within
2025-11-06 Pre-Market 128.35% 0.45% 0.00x Within
2026-05-14 Pre-Market 20.71% 2.37% 0.11x Within
2026-08-11 After-Close 16.67% 5.67% 0.34x Within

Earnings calendar: this week’s reports with expected vs actual moves →

CRDF Options Activity & IV Rank

Volatility Metrics

Current IV: —
7-DTE IV: —
Expected Move: $0.75
7-DTE Move: $0.75
Days to Exp: 25 (2026-11-20)

Options Flow

Call Volume: 343
Put Volume: 37
P/C Volume: 0.108
BULLISH
Call OI: 4,759
Put OI: 47
P/C OI: 0.01
Total OI: 4,806

ATM Options Pricing

ATM Call: $0.38
ATM Put: $0.38
Call %: 46.9%
Put %: 46.9%

Chain Summary

Chain Volume: 929
Chain OI: 32,162
Last Updated: 10/26/2026
Spread Scanner GPU
Full Algorithm Docs ↗

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score (GPU scanner)

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Enter a ticker to scan for optimal spread opportunities.

Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.

Dealer Positioning
TYPICAL γ

Estimated net dealer gamma is at the 36th percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.

Gamma percentile
36%
vs own history
GEX tilt
+0.93
OI-weighted, today
Vanna tilt
+0.91
δ-sensitivity to IV
Charm tilt
-0.92
δ-decay vs time
Vanna tilt +0.91: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.92: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.

Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.

Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.

Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.

This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.

· 3 ATM contracts, 1k total OI
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Wing vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together

Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d —
— pts EXTREME
as of Oct 26 · No data
30 DTE / 10d —
— pts EXTREME
as of Oct 26 · ATM 382.5% / Wing —

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Enter a ticker to render the implied volatility surface.

Volatility Smile

Enter a ticker to render the implied volatility smile.

IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)$0.75Oct 26
Beta Analysis

Risk Metrics

Beta: 1.7329
Alpha: -84.47%
Correlation: 0.2552
R-Squared: 6.5%
Stock Volatility: 86.5%
Market Volatility: 12.7%

Analysis Details

Benchmark: SPY
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own CRDF
4 of 37 tracked investors
InvestorValueShare of their portfolioRankQ/Q sharesSource
Millennium Management Hedge fund
Izzy Englander
$175K
0.00%
#3518 of 3716+484.1%13F
Point72 Hedge fund
Steve Cohen
$37K
0.00%
#1890 of 1945new13F
Rockefeller Capital Management Family office
Rockefeller family
$26K
0.00%
#3647 of 4729-64.6%13F
Renaissance Technologies Hedge fund
Jim Simons
$18K
0.00%
#3098 of 3138-86.2%13F

Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions

CRDF Institutional Ownership (13F)

Latest filings — 2026-09-30
Diluted shares outstanding: 67,765,250 (as of 2026-06-30)

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

106 filers23,174,238 shares$35.62M value34.20% of float
# Filer Shares Value % of Total % of Float Period
1 Vanguard Group Inc Custodian 3,722,085 $10.46M 29.36% 5.49% 2025-12-31
2 Laurion Capital Management LP 3,098,299 $4.03M 11.31% 4.57% 2026-06-30
3 Vanguard Capital Management LLC 2,895,592 $3.76M 10.57% 4.27% 2026-06-30
4 Pfizer Inc 2,411,575 $3.01M 8.46% 3.56% 2026-06-30
5 Franklin Resources, Inc. Custodian 1,205,803 $1.57M 4.40% 1.78% 2026-06-30
6 BlackRock, Inc. Custodian 972,873 $1.26M 3.55% 1.44% 2026-06-30
7 BLAIR WILLIAM & CO/IL 912,513 $1.19M 3.33% 1.35% 2026-06-30
8 Geode Capital Management, LLC Custodian 820,062 $1.07M 2.99% 1.21% 2026-06-30
9 GoalVest Advisory LLC 687,285 $831.62K 2.33% 1.01% 2026-09-30
10 UBS Group AG Custodian 638,699 $830.31K 2.33% 0.94% 2026-06-30
11 Jane Street Group, LLC Custodian 607,900 $790.27K 2.22% 0.90% 2026-06-30
12 Vanguard Fiduciary Trust Co 410,602 $533.78K 1.50% 0.61% 2026-06-30
13 AQR Capital Management, LLC Custodian 346,353 $450.26K 1.26% 0.51% 2026-06-30
14 State Street Corp 331,395 $430.81K 1.21% 0.49% 2026-06-30
15 HRT FINANCIAL LP 272,786 $354.00K 0.99% 0.40% 2026-06-30
16 FLPUTNAM INVESTMENT MANAGEMENT CO 247,474 $321.72K 0.90% 0.37% 2026-06-30
17 Morgan Stanley Custodian 246,095 $319.92K 0.90% 0.36% 2026-06-30
18 BNP Paribas Financial Markets Custodian 228,461 $297.00K 0.83% 0.34% 2026-06-30
19 X-Square Capital, LLC 205,700 $267.00K 0.75% 0.30% 2026-06-30
20 GSA CAPITAL PARTNERS LLP 173,274 $225.00K 0.63% 0.26% 2026-06-30
21 Marshall Wace, LLP Custodian 162,214 $210.88K 0.59% 0.24% 2026-06-30
22 Bank of New York Mellon Corp Custodian 161,689 $210.20K 0.59% 0.24% 2026-06-30
23 Northern Trust Corp Custodian 152,875 $198.74K 0.56% 0.23% 2026-06-30
24 Cubist Systematic Strategies, LLC 88,903 $183.14K 0.51% 0.13% 2025-09-30
25 Avestar Capital, LLC 136,145 $176.99K 0.50% 0.20% 2026-06-30
5 filers$1.04M notional
# Filer Notional Value % of Total Period
1 GROUP ONE TRADING LLC Custodian $528.71K 50.80% 2026-06-30
2 Citadel Advisors LLC Custodian $239.72K 23.03% 2026-06-30
3 Jane Street Group, LLC Custodian $105.30K 10.12% 2026-06-30
4 Wolverine Trading, LLC Custodian $84.45K 8.11% 2025-09-30
5 Simplex Trading, LLC Custodian $82.68K 7.94% 2026-06-30
5 filers$84.94K notional
# Filer Notional Value % of Total Period
1 Wolverine Trading, LLC Custodian $52.83K 62.20% 2025-09-30
2 Citadel Advisors LLC Custodian $16.90K 19.90% 2026-06-30
3 Susquehanna International Group, LLP Custodian $14.69K 17.29% 2026-06-30
4 GROUP ONE TRADING LLC Custodian $260 0.31% 2026-06-30
5 Simplex Trading, LLC Custodian $260 0.31% 2026-06-30

CRDF Insider Trading (Form 4)

Latest: 2026-07-16
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-07-16 Mani Mohindru Chief Executive Officer Buy (P) +34,364 $1.46 $50.0K EDGAR
2026-07-16 Gary W Pace Director Buy (P) +687,285 $1.46 $1000.0K EDGAR
2026-06-22 Mani Mohindru Chief Executive Officer Buy (P) +24,703 $1.21 $29.9K EDGAR
2026-06-22 Gary W Pace Director Buy (P) +30,000 $1.22 $36.6K EDGAR
2026-06-15 Renee P Tannenbaum Director Grant (A) +40,565 opt — EDGAR
2026-06-15 Gary W Pace Director Grant (A) +40,565 opt — EDGAR
2026-06-15 James O Armitage Director Grant (A) +40,565 opt — EDGAR
2026-06-15 Rodney S Markin Director Grant (A) +40,565 opt — EDGAR
2026-06-15 Lale White Director Grant (A) +40,565 opt — EDGAR
2026-04-28 Ajay Aggarwal Chief Operating Officer Grant (A) +400,000 opt — EDGAR
2026-04-16 Joshua B Muntner Chief Financial Officer Award (A) — — EDGAR
2026-04-16 Tod Smeal Chief Scientific Officer Grant (A) +300,000 opt — EDGAR
2026-04-16 Joshua B Muntner Chief Financial Officer Grant (A) +486,650 opt — EDGAR
2026-04-02 Mani Mohindru Chief Executive Officer Grant (A) +600,000 opt — EDGAR
2026-02-18 Mani Mohindru Interim CEO Grant (A) +200,000 opt — EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.

CRDF Insider Holdings

9 insiders · @ $0.80
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 Gary W Pace Director 3,389,337 $2.73M $3.97M 20 2026-07-16
2 James E. Levine Chief Financial Officer 125,316 $100.8K $277.4K 8 2025-03-13
3 Lale White Director 113,788 $91.5K $124.5K 10 2026-06-15
4 Mani Mohindru Chief Executive Officer 59,067 $47.5K $79.9K 9 2026-07-16
5 Rodney S Markin Director 31,060 $25.0K $59.9K 9 2026-06-15
6 James O Armitage Director 27,490 $22.1K $78.5K 10 2026-06-15
7 Mark Erlander Chief Executive Officer 24,481 $19.7K $34.3K 10 2025-03-13
8 Renee P Tannenbaum Director 20,000 $16.1K $51.4K 8 2026-06-15
9 Joshua B Muntner Chief Financial Officer 500 $402 $0 2 2026-04-16
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.

CRDF Board & Officers

As of SEC filings through Jul 16, 2026

Directors 7

Officers 6

Changes in the last 10 years (32)
Apr 27, 2026Ajay Aggarwal became Chief Operating Officer
Apr 6, 2026Joshua B Muntner became Chief Financial Officer
Apr 2, 2026Mani Mohindru listed as Chief Executive Officer (previously Interim CEO) in SEC filings
Feb 18, 2026Mani Mohindru first listed as Interim CEO in an SEC filing
Jan 27, 2026The company announced the departure of Mark Erlander as Chief Executive Officer in an SEC filing
Jan 27, 2026The company announced the departure of James E. Levine as Chief Financial Officer in an SEC filing
Jan 27, 2026Brigitte Ute Lindsay became Chief Accounting Officer
Jun 16, 2025Roger Sidhu became Chief Medical Officer
Jun 13, 2025The company announced the departure of Fairooz Kabbinavar as Chief Medical Officer in an SEC filing
Jan 30, 2023Fairooz Kabbinavar became Chief Medical Officer
Apr 12, 2022The company announced the departure of Katherine L Ruffner as Chief Medical Officer in an SEC filing
Jan 10, 2022Tod Smeal became Chief Scientific Officer
Jul 12, 2021James E. Levine became Chief Financial Officer
Jul 6, 2021Katherine L Ruffner became Chief Medical Officer
Jun 14, 2021Mark Erlander first listed as a director in an SEC filing
Jun 10, 2021Renee P Tannenbaum became a director
Jun 10, 2021Mani Mohindru became a director
Jan 5, 2021Mark Erlander no longer listed as a director in SEC filings
Sep 30, 2020Rajeev M. Shah became a 10% owner
Sep 30, 2020Ra Capital Management, L.p. became a 10% owner
Not reported recently (11)
  • Vicki Kelemen · Last reported as Exec. VP and COO in an SEC filing dated Mar 16, 2023
  • John P Brancaccio · Last reported as a director in an SEC filing dated Mar 10, 2022
  • Gary S Jacob · Last reported as a director in an SEC filing dated Mar 23, 2021
  • Rajeev M. Shah · Last reported as a 10% owner in an SEC filing dated Oct 2, 2020
  • Peter Kolchinsky · Last reported as a 10% owner in an SEC filing dated Oct 2, 2020
  • Ra Capital Management, L.p. · Last reported as a 10% owner in an SEC filing dated Oct 2, 2020
  • Thomas Phd Adams · Last reported as a director in an SEC filing dated Jun 19, 2020
  • Athena Countouriotis · Last reported as a director in an SEC filing dated Jun 24, 2019
  • Stanley Tennant · Last reported as a director in an SEC filing dated Jun 13, 2018
  • William J Welch · Last reported as Chief Executive Officer in an SEC filing dated Feb 1, 2018
  • Paul Billings · Last reported as a director in an SEC filing dated Jan 25, 2018
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
ETF Holders
4 ETFs hold CRDF
4 shown · $3.63M total exposure · 0.02% AUM-weighted avg weight
# ETF Provider Weight $ Exposure ETF AUM As Of
1 VTI Vanguard Morningstar Total Stock Market ETF Vanguard 0.00% $2.5M — 2026-09-30
2 VXF Vanguard Extended Market ETF Vanguard 0.00% $918,778 — 2026-09-30
3 IWC iShares Micro-Cap ETF iShares (BlackRock) 0.02% $204,766 $1.2B 2026-10-23
4 MSSM Morgan Stanley Pathway Small-Mid Cap Equity ETF Nport 0.00% $2,970 — 2026-05-31
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

Trailing P/E
—
TTM Diluted EPS
$-0.60
TTM Revenue
$508.00K
TTM Net Income
$-40.08M
TTM Op. Cash Flow
$-40.85M
Quarterly figures (12 quarters)
QuarterPeriod EndRevenueNet IncomeDiluted EPSOp. Cash Flow
Q2 '262026-06-30$104.00K$-9.24M$-0.14$-11.77M
Q1 '262026-03-31$41.00K$-12.35M$-0.18$-12.29M
Q4 '252025-12-31$243.00K$-7.22M$-0.11$-5.97M
Q3 '252025-09-30$120.00K$-11.26M$-0.17$-10.83M
Q2 '252025-06-30$121.00K$-13.95M$-0.21$-8.33M
Q1 '252025-03-31$109.00K$-13.44M$-0.20$-12.79M
Q4 '242024-12-31$151.00K$-11.79M$-0.21$-10.27M
Q3 '242024-09-30$165.00K$-11.86M$-0.25$-10.46M
Q2 '242024-06-30$163.00K$-11.78M$-0.26$-9.23M
Q1 '242024-03-31$205.00K$-10.02M$-0.22$-7.74M
Q4 '232023-12-31$156.00K$-9.34M$-0.21$-7.14M
Q3 '232023-09-30$141.00K$-9.74M$-0.22$-7.96M
Q2 2026 • period ending 2026-06-30 • filed 2026-08-11
Valuation

Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.

Price Multiples
  • P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
  • P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
  • P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
  • EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
  • EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
  • ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
  • ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
  • Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
  • FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
  • Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
  • Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
  • Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
  • Multiples expanding while earnings are flat = sentiment-driven rally.
  • Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
2.05
P/S
107.29
EV/EBITDA
—
EV/Sales
89.19
ROE
-151.0%
ROA
-107.4%
Div Yield
0.00%
FCF Yield
-74.96%
Debt/Equity
0.00
Current Ratio
—
Market Cap
$54.50M
as of 2026-10-26
Short Interest & Float

Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.

Metric definitions
  • Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
  • SI % of Float — short interest / free float. The key crowding metric.
  • Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
  • Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
  • Free Float — shares available for public trading (total shares minus insider / restricted).
  • Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
  • SI % of Float < 5% — typical, no particular signal.
  • 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
  • 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
  • >30% — extreme; borrow is likely expensive and squeeze risk is material.
  • Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
  • Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
  • A sudden drop in SI after a rally may indicate a squeeze in progress.

Short interest is reported mid-month and end-of-month; short volume is daily.

Short Interest
12.07M
SI % of Float
17.62%
Days to Cover
17.19
Short Vol Ratio
43.2%
Free Float
68.53M
Float %
88.1%
Short interest 2026-09-30 • Short volume 2026-10-26 • Float 2026-08-26